For in vitro cytotoxicity assays where benzyl alcohol vehicle effects could confound results, include matched Bacteriostatic Water vehicle controls at the same final benzyl alcohol concentration as the peptide treatment to distinguish compound-specific from vehicle-associated biological effects
In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
Many of BPC-157s researched benefits are related to gut health and systemic healing
Glucose-tolerance and insulin-sensitivity measurements changed in obese mice
Systemic inflammatory conditions, joint inflammation, and whole-body inflammation reduction all benefit from the higher bioavailability of subcutaneous delivery, which bypasses first-pass gut metabolism